Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. DuoGenic StemCells's Revenue for the
six
months ended in Dec. 2025 was NT$10.29 Mil. DuoGenic StemCells's average Accounts Receivable for the
six
months ended in Dec. 2025 was NT$2.81 Mil.
Hence, DuoGenic StemCells's Receivables Turnover for the
six
months ended in Dec. 2025 was 3.66.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
DuoGenic StemCells Receivables Turnover Related Terms
DuoGenic StemCells Receivables Turnover Historical Data
* Premium members only.
The historical data trend for DuoGenic StemCells's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:7607 vs VRTX, REGN, RVMD: Receivables Turnover Comparison
For the Biotechnology subindustry, DuoGenic StemCells's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DuoGenic StemCells Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, DuoGenic StemCells's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where DuoGenic StemCells's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DuoGenic StemCells (ROCO:7607) has a Receivables Turnover of 3.66 as of Dec. 2025. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on DuoGenic StemCells and its competitors. According to the industry distribution chart, DuoGenic StemCells ranks #303 out of 841 companies in the Biotechnology industry, placing it in the top 36%.
Is DuoGenic StemCells' Receivables Turnover too high?
DuoGenic StemCells' current Receivables Turnover is 3.66. The Biotechnology industry median Receivables Turnover is 5.27. DuoGenic StemCells' value of 3.66 is 30.6% below this industry median. Based on the distribution chart, DuoGenic StemCells ranks #303 out of 841 companies in the Biotechnology industry, which is above the industry midpoint. Overall, DuoGenic StemCells has a GF Score™ of 24/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does DuoGenic StemCells' Receivables Turnover compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, DuoGenic StemCells ranks #303 out of 841 companies for Receivables Turnover. This puts DuoGenic StemCells in the upper half of its industry. The industry median Receivables Turnover is 5.27. DuoGenic StemCells' value of 3.66 is 30.6% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.27, based on 841 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. DuoGenic StemCells's current Receivables Turnover of 3.66 is 30.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on DuoGenic StemCells and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. DuoGenic StemCells's current Receivables Turnover is 3.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DuoGenic StemCells stock overvalued right now?
Based on GuruFocus' analysis, DuoGenic StemCells (ROCO:7607) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$51.51, compared to a current price of NT$13.00 — trading 74.8% below its estimated fair value. The current Receivables Turnover is 3.66 and 30.6% below the Biotechnology industry median of 5.27. DuoGenic StemCells' overall GF Score™ is 24/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For DuoGenic StemCells (ROCO:7607), the current Receivables Turnover is 3.66 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is DuoGenic StemCells (ROCO:7607) Overvalued in 2026?
Based on GuruFocus' analysis, DuoGenic StemCells stock appears to be undervalued.
The current stock price of NT$13.00 is trading 74.8% below its estimated GF Value™ of NT$51.51.
GuruFocus considers DuoGenic StemCells to be Significantly Undervalued.
Key valuation signals for ROCO:7607:
Receivables Turnover: 3.66
GF Value™: NT$51.51 vs. price of NT$13.00 (74.8% below fair value)
Industry Position: 30.6% below the Biotechnology median (#303 of 841)
No single metric tells the full story. See the ROCO:7607 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
DuoGenic StemCells Corp is a company having a team of passionate researchers focused on stem cell cultivation. Their products are intended for research use and can be upgraded for clinical applications. It also develops blood cell therapy programs, using the isolation and purification of blood mononuclear cells to remove granule cells that promote inflammation, and conducts clinical trials on various degenerative diseases to provide a convenient and simple new option for cell therapy.
24GF Score
Get the complete analysis for ROCO:7607
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:7607 has been successfully added to your 
